Loading, please wait...
| REQUEST PARKING » | MAP & DIRECTIONS » |
RESIDENT SEMINAR SCHEDULE
Wednesday, November 11, 2020
St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis
Academic Research Building (ARB) and Virtually
|
|
ARB 337
|
ARB 406
|
ARB 469
|
|
SESSION 1
12:15 pm – 1:00 pm
|
Caroline Patz, Pharm.D.
Novel Therapies in Neonatal Abstinence Syndrome |
Adam Robinson, Pharm.D.
Emerging targets for Multiple myeloma: B-cell maturation Antigen (BCMA) Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy |
Ashley Shuman, Pharm.D.
Prophylaxis and Treatment of Venous Thromboembolism in Oncology Patients |
|
1:00 pm – 1:05 pm
|
Break for Transition between Speakers
|
||
|
SESSION 2
1:05 pm – 1:50 pm
|
Heejung Woo, Pharm.D.
Roles of Omega-3 Fatty Acids in Cardiovascular Health |
Aileen Scheibner, Pharm.D.
Do Vitamin C and Thiamine Really Make a Difference in the ICU? |
Borden Edgar, Pharm.D.
Vancomycin: AUC/MIC versus Trough Based Dosing in the Pediatric Population |
Please join us for the fifth Resident Seminar session of the 2020-2021 academic year. Presented by PGY1 and PGY2 residents from within the St. Louis area, this series focuses on current therapeutic topics in the practice of pharmacy. All sessions will be held in the classrooms in the Academic & Research Building (ARB) on the third and fourth floors, as well as virtually.
* Participants may earn a maximum possible 0.75 contact hour of CPE credit per session. The maximum possible credit that can be earned is 1.50 contact hours. Participants must complete an evaluation to receive credit.
REGISTRATION & PARKING INFORMATION
Live registrations are submitted by RPDs and through survey monkey only. Due to a limited number of live available classroom spaces, a maximum of 22 people are allowed per classroom. Virtual registrations are limitless and completed through survey monkey. Please note, this event has multiple concurrent sessions.
Registration is free, but is required in advance. Due to limited space, only those participants who register before 5:00 PM on Friday, November 6, 2020 will be able to request parking access on campus.
PARKING: To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here>>>. If you do not request parking on our campus, or if you do not submit your request by the deadline, you will be re-directed upon arrival.
HANDOUTS: Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
ATTENDANCE: All live participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against completed evaluations. Attendance for the virtual sessions will be captured once a participant joins the session and will be reconciled with completed evaluations. Any sessions that you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT: Immediately following the presentation, registered participants will receive an email with a link to the evaluation. Within one week after attending the session, participants must complete this online evaluation. The CPE Administrator will submit each participant’s NABP number and date of birth combination to CPE Monitor for continuing education credit, no later than two weeks after the live presentation. Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign or the attendance roster within Microsoft Teams Meeting, the offending participant forfeits CE credit.
It is recommended that participants log on and review the information under "My Account" prior to completing evaluations. The NABP ePID and date of birth fields must be accurate for credit reporting to occur. Participants are encouraged to check their NABP eProfiles for receipt of credit within two weeks of submitting their evaluation(s). If a participant notices an error in credit on their NABP e-profile, they are encouraged to contact Nicole Fields at Nicole.Fields@uhsp.edu soon as possible. To best comply with ACPE's CE credit reporting policy, the University of Health Sciences and Pharmacy is unable, for any reason, to award or correct CE credit if more than 60 days have passed from the event.
After one week, evaluations will close and CPE credit may no longer be claimed. If the deadline is missed or if a CE credit correction must be issued, an additional fee may be incurred for late submission - please see our policy, located on the FAQ page for details. Evaluations close November 18, 2020 at 11:59 PM (CDT).
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify Nicole Fields via email at Nicole.Fields@uhsp.edu in advance so that she may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Nov 11, 2020 12:00 PM - 02:00 PM
Fee
$0.00
CE Hours
4.50
Activity Type
- Knowledge
Neonatal abstinence syndrome (NAS) is a constellation of symptoms resulting from autonomic and central nervous system dysfunction that occurs when an infant withdraws from in utero opioid exposure. NAS is a growing problem in the United States, with the rate of NAS-related neonatal intensive care unit admissions increasing rapidly, and 7 newborns diagnosed with NAS for every 1000 newborn hospital stays. Additionally, the healthcare costs of hospitalized infants with NAS are significantly higher than costs of hospitalized infants without NAS, largely due to their extended hospital stay. This presentation will review the current recommendations for pharmacologic treatment of NAS and examine the most recent literature regarding novel therapies currently being studied for efficacy in NAS.
Objectives
- Describe the current recommendation from the American Academy of Pediatrics regarding first line pharmacologic therapy in Neonatal Abstinence Syndrome (NAS).
- Discuss the literature relating to the efficacy of NAS alternative and adjunct agents clonidine, buprenorphine, and gabapentin.
Speaker(s)/Author(s)
|
Caroline Patz, Pharm.D. |
Activity Number
0033-0000-20-066-L01-P
Date:
11/11/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 337 and Virtually
The treatment armamentarium for multiple myeloma has significantly expanded in the past decade, with various new drug approvals and therapeutic targets. These approvals have improved prognosis and survival of patients with multiple myeloma, though relapse is still common. Multiply-relapsed disease carries a poor prognosis, and there is a need for new therapies and novel therapeutic targets. Given success in other malignancies, chimeric antigen receptor (CAR) T-cell therapy is currently under investigation as a means to improve outcomes for patients for patients with multiply relapsed disease. Relatively few pharmacists have encountered these agents in clinical practice or have been exposed to preliminary data surrounding their use. This seminar will attempt to provide education surrounding CAR T-cell therapies in relapsed or refractory multiple myeloma and preliminary efficacy and safety data surrounding some of the agents currently being studied.
Objectives
- Describe attributes of B-cell maturation antigen (BCMA) that make it a viable chimeric antigen receptor (CAR) T-cell target.
- Identify advantages of CAR T-cell therapy in relapsed and refractory multiple myeloma (R/R MM).
Speaker(s)/Author(s)
|
Adam Robinson, Pharm.D. |
Activity Number
0033-0000-20-068-L01-P
Date:
11/11/20
Time:
12:15 PM - 01:50 PM
CE Hours
0.75
Location
ARB 406 and Virtually
This CE presentation will explore the updated treatment options and prophylaxis options added to guidelines for the management of cancer-associated venous thromboembolism. Pertinent literature of the new treatment and prophylaxis options recommended will be evaluated to determine how each agent effects patients with cancer as far efficacy and safety of anticoagulants and adverse events. This will serve to help pharmacists understand the place of therapy for the different anticoagulants used for prevention and treatment of cancer-associated venous thromboembolism.
Objectives
- Summarize current guideline recommendations and literature relating to the pharmacologic treatment and prophylaxis of cancer-associated venous thromboembolism.
- Identify limitations for the use of VTE prophylaxis and treatment regimens in patients with cancer.
Speaker(s)/Author(s)
|
Ashley Shuman, Pharm.D. |
Activity Number
0033-0000-20-069-L01-P
Date:
11/11/20
Time:
12:15 PM - 01:00 PM
CE Hours
0.75
Location
ARB 469 and Virtually
Cardiovascular disease is the leading cause of death in the United States. One of the risk factors for cardiovascular disease is elevated lipid levels, including triglycerides. Omega-3 fatty acids are known to reduce triglyceride levels; they are recommended as an adjunct therapy for managing hypertriglyceridemia in the 2018 AHA/ACC guideline. Recent clinical trials have demonstrated the benefits of omega-3 fatty acids in patients with increased risk of cardiovascular diseases. However, previous studies have shown mixed results of their role in cardiovascular health. This presentation will provide backgrounds on different types and formulations of omega-3 fatty acid products currently available, along with their potential mechanism of action. The current clinical guidelines and primary literature will then be reviewed to describe the omega-3 fatty acids’ role in cardiovascular outcomes.
Objectives
- Identify the prevalence of cardiovascular disease (CVD) and omega-3 fatty acid use in the United States.
- Discuss different types and formulations of omega-3 fatty acids, and their potential mechanisms for cardiovascular protection.
- Summarize the role of omega-3 fatty acids in current clinical guidelines and literature on cardiovascular outcomes.
Speaker(s)/Author(s)
|
Heejung Woo, Pharm.D. |
Activity Number
0033-0000-20-067-L01-P
Date:
11/11/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 337 and Virtual
This program will take a deep dive into the literature exploring the use of vitamin C and thiamine within the intensive care unit with a focus on indications other than septic shock. The physiology of vitamin C and thiamine will be reviewed and an overview of the literature surrounding these alternative indications will be presented.
Objectives
- Describe the physiological importance of vitamin C and thiamine
- Identify critically ill populations in which vitamin C and thiamine may improve clinical outcomes
Speaker(s)/Author(s)
|
Aileen Scheibner, Pharm.D. |
Activity Number
0033-0000-20-074-L01-P
Date:
11/11/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 406 and Virtually
Vancomycin is an effective antibiotic for multi-drug resistant gram positive organisms. It is a time-dependent, bactericidal glycopeptide. However, it does not come without concern for serious adverse side effects. Nephrotoxicity is the most concerning side effect. This makes achieving a therapeutic dose while avoiding nephrotoxicity quite challenging, especially in the pediatric population. New recommendations for the therapeutic monitoring of vancomycin recommend targeting an AUC/MIC of 400 to 600 mg*hr/L. These recommendations differ from previous trough based monitoring. New evidence shows that there is an increase in incidence of nephrotoxicity when therapeutic monitoring is based on trough based dosing. This educational seminar will review the current literature and discuss the benefits and disadvantages of each dosing methods use in the pediatric population.
Objectives
- Identify the mechanism of action, pharmacodynamics, and pharmacokinetics of vancomycin.
- Identify risks and benefits associated with trough based vancomycin dosing.
- Identify risks and benefits associated with AUC/MIC vancomycin dosing.
Speaker(s)/Author(s)
|
Borden Edgar, Pharm.D. |
Activity Number
0033-0000-20-065-L01-P
Date:
11/11/20
Time:
01:05 PM - 01:50 PM
CE Hours
0.75
Location
ARB 469 and Virtually
